This paper is entitled, “Supplementation with Specialized Pro-Resolving Mediators Reduces Inflammatory Biomarkers and Improves Reported Clinical Symptomology in Subjects with Chronic Inflammatory Conditions: Results from a Multi-Center Open-Case Series”
- Inflammation has 2 phases: initiation and resolution. Many chronic health issues are linked to unresolved inflammation
- Specialized pro-resolving mediators (SPMs) are endogenous molecules essential for resolution of inflammation but may not be produced in required levels in certain condition
- Multi-center case study assessed effects of a proprietary SPM supplement (LM-O3) on inflammatory biomarkers in 34 men and women (21-75 y/o) with conditions indicating raised inflammatory tone
- Results showed a 43% reduction in high-sensitivity C-reactive protein (hs-CRP) at 4 weeks with concurrent reduction in prostaglandin E2 (PGE2)
- At 8 weeks, hs-CRP remained reduced, and PGE2 was reduced to within normal range
- Functional measurements including reported measures of pain as well as quality of life indicated continued improvement at 4 and 8 weeks
- Adverse events were minimal and managed without incident.
Inflammation complicates the management of many conditions such as obesity, metabolic syndrome, cardiovascular disease and diabetes. The inability to resolve both acute and chronic inflammation leads to progression and often complications of the disease state later on. Thus, improved management of an elevated inflammatory response is an important objective in patient care. This single-arm, practice-based observation study provides preliminary evidence that direct treatment with SPMs represents a potential novel approach in promoting inflammation resolution.